朗姿股份有限公司 2025 年半年度报告 2025-0xx 【披露时间】 2025 年 06 月 30 日 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：朗姿股份有限公司 单位：元 朗姿股份有限公司 2025 年半年度报告全文 2、母公司资产负债表 单位：元 | 长期应收款 | 0.00 | 0.00 | | --- | --- | --- | | 长期股权投资 | 870,148,615.49 | 921,871,427.11 | | 其他权益工具投资 | 5,682,126.31 | 5,577,740.47 | | 其他非流动金融资产 | 471,486,774.16 | 439,011,966.41 | | 投资性房地产 | 284,691,724.18 | 304,116,464.31 | | 固定资产 | 712,585,974.97 | 700,596,659.34 | | 在建工程 | 20,070,944.61 | 14,342,031.44 | | 生产性生物资产 | 0.00 | 0. ...

2025 年上半年非经营性资金占用及其他关联资金往来 情况汇总表 | | | | | | | | | | | | | | | | 单位：元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非 经 营性 | | 资金占用方名 | 占用方与 上市公司 | 上市公司 | 2025 | 年期初占用 | 2025 | 年上半年占 | 2025 年上半 | 2025 年上半年偿 | 2025 | 年上半年期 | 占用形成 | | 占用性 | | | | | | 核算的会 | | | | 用累计发生金额 | 年占用资金的 | | | | | | | | 资金占用 | | 称 | 的关联关 | 计科目 | | 资金余额 | （不含利息） | | 利息(如有) | 还累计发生金额 | | 末占用资金余额 | 原因 | | 质 | | | | | 系 | | | | | | | | | | | | | | 控股股东、 | | | | | | | | | | | | | | | ...

股票代码：002612 公告编号：2025-050 纵向美化中轴线 横向轻盈中面部 2025 年半年度报告 朗 姿 股 份 有 限 公 司 朗姿股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人申东日先生、主管会计工作负责人侯立成先生及会计机构负 责人蒋琼女士(会计主管人员)声明：保证本半年度报告中财务报告的真实、 准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来发展规划和经营计划等前瞻性陈述，不构成公司对投资者 的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当 理解规划、计划、预测与承诺之间的差异。 公司需遵守《深圳证券交易所上市公司自律监管指引第 3 号——行业信 息披露》中的"纺织服装相关行业"的披露要求。 公司分别在本报告"第三节 管理层讨论与分析"中"一、报告期内公司从事 的主要业务"部分描述了相关行业情况等外部因素，在"十二、公司面临的风 险和应对措施"部分描述了公司可能面对的风险 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-049 朗姿股份有限公司 第五届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第三十三 次会议通知于 2025 年 8 月 26 日以传真、邮件等通知方式发出，经 5 位董事一致 同意，于 2025 年 8 月 28 日以通讯及现场会议方式召开。会议由董事长申东日先 生主持，会议应出席董事 5 人，实际出席 5 人。公司高级管理人员列席了本次会 议。本次会议的召开符合《中华人民共和国公司法》《朗姿股份有限公司章程》 《朗姿股份有限公司董事会议事规则》的有关规定，合法有效。 三、备查文件 朗姿股份第五届董事会第三十三次会议决议。 1、审议并通过了公司《2025 年半年度报告》及《2025 年半年度报告摘要》 董事会认为：公司《2025 年半年度报告》及《2025 年半年度报告摘要》符 合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整，不存在任何虚假记 ...

Core Insights - The forum highlighted the latest advancements in aesthetic medicine, focusing on trends and technologies in the Asian market [1] Group 1: Key Achievements - Launch of the ReNature aesthetic system, which emphasizes three styles: "youthful, intelligent, and original," and utilizes the "HOOD" four-dimensional analysis method to promote natural and personalized beauty [2] - Introduction of the V-Line chin support technology, designed to address common issues in Asian facial structures, enhancing side profile contours [2] - Release of the high-end filler material "Funiwei·Zhiya Pro," a new generation hyaluronic acid product known for its high cohesiveness, strong support, and safety [2] Group 2: Academic Contributions - Presentation by Professor Wu Suofan on the anatomical basis and scientific rationale behind the ReNature system [3] - Speech by Liow Tiong Sin on the importance of V-Line chin support in Asian facial aesthetics [3] - Dr. Ma Yao's interpretation of the ReNature aesthetic strategy, showcasing clinical applications through case studies [3] Group 3: Strategic Developments - Announcement of the enhancement of the "Micro-Beauty Expert Team," comprising experienced doctors in facial sculpting and aesthetic treatments [3] - The forum aimed to establish an international academic exchange platform in the aesthetic medicine field, supported by participation from numerous experts [3]

Core Viewpoint - The financing activities of Langzi Co., Ltd. indicate a moderate interest from investors, with recent net purchases reflecting a cautious but positive sentiment in the market [1] Financing Activities - On August 25, Langzi Co., Ltd. recorded a financing buy amount of 0.27 billion, ranking 2290th in the market [1] - The financing repayment amount on the same day was 0.23 billion, resulting in a net purchase of 4.5079 million [1] - Over the last three trading days (August 21-25), the financing buy amounts were 0.46 billion, 0.30 billion, and 0.27 billion respectively [1] Securities Lending - On August 25, the company experienced a securities lending sell of 23,200 shares, with a net sell of the same amount [1]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a recovery, with high growth in premium and fashionable segments, particularly in gold jewelry and beauty care [23][27] - The report emphasizes the importance of emotional consumption themes driving growth in high-quality companies within the sector [30] Summary by Sections Retail Market Review - The retail industry index rose by 4.21% during the week of August 18-22, 2025, outperforming the Shanghai Composite Index by 2.20 percentage points [12][20] - The internet e-commerce sector showed the highest growth, with a weekly increase of 7.71% [13][17] - Year-to-date, the jewelry sector has led with a 33.74% increase [13][17] Retail Insights: Mid-Year Reports - Gold jewelry companies like Laopuhuang and Chaohongji reported significant revenue growth, with Laopuhuang achieving a revenue of 12.354 billion yuan (+251.0%) and a net profit of 2.268 billion yuan (+285.8%) [23][35] - Beauty care brands such as Shanghai Jahwa and Runben also showed positive performance, with Shanghai Jahwa reporting a net profit of 266 million yuan (+11.7%) [27][38] Focus on High-Quality Companies - Investment focus includes: - Gold jewelry brands with differentiated product offerings, recommending Laopuhuang and Chaohongji [30][32] - Offline retail companies adapting to trends, recommending Yonghui Supermarket and Aiyingshi [30][32] - High-quality domestic beauty brands, recommending Maogeping and Pola [30][32] - Medical beauty product manufacturers, recommending Aimeike and Kedi-B [30][32] Company-Specific Highlights - Laopuhuang: Achieved a revenue of 12.354 billion yuan (+250.9%) and a net profit of 2.268 billion yuan (+285.8%) in H1 2025, with strong brand expansion and channel upgrades [35][36] - Runben: Reported a revenue of 895 million yuan (+20.3%) and a net profit of 188 million yuan (+4.2%) in H1 2025, focusing on expanding its product matrix [38][40] - Aiyingshi: Achieved a revenue of 1.835 billion yuan (+8.3%) and a net profit of 46.74 million yuan (+10.2%) in H1 2025, with steady store expansion [42]

Group 1 - The core viewpoint of the article highlights the fluctuating investment and financing trends in China's medical beauty industry, with a peak in 2016 and a decline thereafter [1][17] - Investment events peaked in 2016 with 19 occurrences and an investment amount of 1.353 billion RMB, while the highest investment amount was recorded in 2018 at 2.374 billion RMB [1] - By 2024, only 3 investment events occurred with a total investment of 150 million RMB, and as of June 5, 2025, only 1 event with an investment of 30 million RMB was reported [1] Group 2 - The majority of investment rounds in the medical beauty industry are concentrated in early stages, particularly angel and A-round financing [2] - The industry encompasses various fields such as medical beauty raw materials, equipment, and service platforms, indicating strong innovation and technical barriers [2] Group 3 - Investment activities are primarily concentrated in Beijing and Guangdong, with 49 and 23 financing events respectively, followed by Sichuan and Shanghai with 12 and 9 events [4] - The focus on these regions is attributed to the concentration of resources and opportunities in the medical beauty sector [4] Group 4 - The investment direction is primarily focused on the construction of medical beauty platforms [6] Group 5 - The main investment entities in the medical beauty industry are capital organizations, accounting for 73% of the total, while industrial entities like Gree Electric and Xiaomi Group make up 27% [5] Group 6 - There are few industry investment funds specifically targeting medical beauty, with only 2 private funds identified [13] Group 7 - Recent years have seen a trend of horizontal acquisitions among midstream enterprises in the medical beauty industry as a means to expand scale [15] - Notable acquisition events include 康哲药业 acquiring 旭俐医疗 with a 100% stake and 新氧 acquiring 奇致激光 [16] Group 8 - Overall, the investment and financing landscape in China's medical beauty industry has shown fluctuations, with a concentration of activities in Beijing and Guangdong, primarily driven by capital investment institutions [17]

Core Viewpoint - Langzi Co., Ltd. has approved a guarantee for its wholly-owned subsidiary, Sichuan Jingfu Medical Beauty Hospital, to secure a loan of 10 million yuan from China Bank, with a total external guarantee limit set at 3.05 billion yuan for 2025 [2][5]. Summary by Sections Guarantee Overview - The total external guarantee limit for Langzi Co. and its subsidiaries for 2025 is capped at 3.05 billion yuan, with 2.4 billion yuan allocated for subsidiaries with a debt-to-asset ratio below 70% and 650 million yuan for those above [2]. - As of the announcement date, the total external guarantee balance is 1.09216 billion yuan, representing 39.18% of the company's audited net assets for 2024 [2][7]. Details of the Guaranteed Party - Sichuan Jingfu Medical Beauty Hospital, wholly owned by Langzi Co., has a registered capital of 20 million yuan and was established on April 30, 2005 [6][7]. - The hospital is not listed as a dishonest executor [7]. Guarantee Agreement Main Points - The guarantee is a joint liability guarantee for a loan of 10 million yuan, with a guarantee period of three years from the debt performance deadline [7]. - The guarantee covers principal, interest, penalties, and other related costs [7]. Board of Directors' Opinion - The board believes that providing this guarantee will support the subsidiary's business development and will not negatively impact the company's operations or shareholder interests [7]. Cumulative External Guarantee Amount - The cumulative external guarantee amount for the company and its subsidiaries is 1.828 billion yuan, with no overdue guarantees or litigation-related guarantees reported [8].

（文章来源：证券日报） 证券日报网讯 8月22日晚间，朗姿股份发布公告称，截至本公告披露日，公司及控股子公司的担保额度 总金额为182，800万元，对外担保总余额为109，216万元（此处总金额与总余额的统计为剔除多方担保 时重复计算的金额），占公司2024年度经审计净资产的39.18%。公司及控股子公司无逾期对外担保、 无涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...